Tag Archives: Warning Letter

FDA Warning Letters – Their Relationship to Drug Shortages

The FDA has become keenly aware within the past several years of the impact that their audits have on the availability of drugs becoming available to the consuming public.  Douglas C. Throckmorton, MD, Deputy Director for Regulatory Affairs, CDER, FDA … Continue reading

Posted in FDA Compliance, Regulatory Compliance, Warning Letters | Tagged , , , , , , | Leave a comment

NEW ADDITION TO WARNING LETTERS’ “BOILERPLATE” PARAGRAPHS

CDER RESPONDS TO MANAGEMENT OF LACK OF AVAILABILITY OF FINISHED DRUG PRODUCT OR API Recently the FDA has added a new standardized paragraph to each of its Warning Letters for both Finished Drug Products and for Active Pharmaceutical Ingredients.  Please … Continue reading

Posted in FDA Compliance, Regulatory Compliance, Uncategorized, Warning Letters | Tagged , , , , , , | Leave a comment

IMPORT ALERT FINDING GREATER USAGE WITHIN FDA’S BAG OF “WEAPONS”

GULF PHARMACEUTICAL INDUSTRIES (02/23/12), NOBILUS ENT (03/07/12) and LABORATORIOS JALOMA S.A. de C.V. (03/9/12) ALL RECEIVE IMPORT ALERTS WITHIN ONE MONTH AS PART OF THEIR WARNING LETTERS The FDA has recently begun to use within their CDER Warning Letters the following terminology on a … Continue reading

Posted in FDA Compliance, Import Ban, Regulatory Compliance | Tagged , , , , , | Leave a comment

WINTAC LIMITED INDIA RECEIVES FDA WARNING LETTER (022312)

CITES ASEPTIC MANUFACTURING FACILITY FOR SIGNIFICANT cGMP VIOLATIONS Specific violations observed during the inspection include, but are not limited, to the following: 1. Your firm has not established or followed appropriate written procedures designed to prevent microbiological contamination of drug … Continue reading

Posted in FDA Compliance, Regulatory Compliance, Warning Letters | Tagged , , , , , , , , | Leave a comment

CHINESE API MANUFACTURING FACILITIES RECEIVE WARNING LETTER (MARCH 30, 2011)

NINGBO SMART PHARMACEUTICAL RELEASE WITH INCOMPLETE C of As Comment The Ningbo Smart Pharmaceutical Co. Ltd, Ningbo China, received an Active Pharmaceutical Ingredient (API) audit between October 25-29, 2010.  During this audit, the investigator identified significant deviations from CGMP for the manufacture of … Continue reading

Posted in FDA Compliance, Warning Letters | Tagged , , , , , , , , , , , , ,

WARNING LETTER SANOFI AVENTIS DEUTSCHLAND GmbH

WARNING LETTER  FEBRUARY 9, 2011 SANOFI AVENTIS DEUTSCHLAND GmbH (con’t) 2. Your firm has not established separate or defined areas or such other control systems as necessary to prevent contamination or mix-ups during aseptic processing. [21 C.F.R. § 211.42(c)]. For example,  a) The airflow velocity inside critical … Continue reading

Posted in FDA Compliance, Warning Letters | Tagged , , , , | Leave a comment

Steris Corporation Warning Letter February 9, 2011

 Warning Letter  February 9, 2011 Steris Corporation “Chemical Indicators (Verify SixCess Class 6 Challenge Packs and Chemical Indicators) Should Not Replace Biological Indicators (BIs)” Comment Steris Corporation has developed chemical indicators that have been approved by the FDA to “monitor physical … Continue reading

Posted in FDA Compliance, Warning Letters | Tagged , , , , , | 1 Comment